Drug Trial Radar · NCT05198505
Clinical Trial of TQB2868 Injection in Subjects With Advanced Malignant Tumors
Last checked: Nov 20, 2026Latest source record: May 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
280
Planned (sponsor's estimate)
Start
Apr 27, 2022
Primary completion
Jun 2023
Study completion Jun 2024
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 20, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The TQB2868 protein in this study targeted programmed cell death protein 1 (PD-1) and transforming growth factor-β (TGF-β). The bifunctional fusion protein targets and neutralizes TGF-β in the tumor microenvironment. On the basis of inhibiting PD-1 / programmed death ligand 1 (PD-L1) pathway, T cells can restore activity, enhance immune response, and more effectively improve the effect of inhibiting tumor occurrence and development.
Conditions
- Advanced Malignant Tumor
Interventions
TQB2868 InjectionDrug
TQB2868 protein is a bi-functional fusion protein targeting PD-1 and TGF-β
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity (DLT)Time frame: up to 10 months
- Recommended Phase II Dose (RP2D)Time frame: up to 10 months
- Maximum Tolerated Dose (MTD)Time frame: up to 10 months
- All adverse events (AE), serious adverse events (SAE), and treatment-related adverse events (TEAEs)Time frame: up to 17 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Linyi Cancer Hospital
Linyi, Shandong, China · Recruiting
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.